

# 6<sup>th</sup> Asia-Pacific Pharma Congress

July 11-13, 2016 Kuala Lumpur, Malaysia

## Concise total synthesis of (-)-protoemetinol

Changjin Lim<sup>1</sup>, Hyunyoung Moon<sup>1</sup>, Kyeojin Kim<sup>1</sup>, Jaehoon Sim<sup>1</sup>, Seyeon Hwang<sup>1</sup>, Hongchan An<sup>1</sup>, Seung-Mann Paek<sup>2</sup> and Young-Ger Suh<sup>1</sup><sup>1</sup>Seoul National University, Republic of Korea<sup>2</sup>Gyeongsang National University, Republic of Korea

Benzo[ $\alpha$ ]quinolizidine alkaloids have received constant attention because of their multiple pharmacological interests. Particularly, Emetine, which acts as a protein synthesis inhibitor and DNA interacting agent has been clinically used for the treatment of a protozoan infection. Recently, additional biological activities, including antiviral properties and NF- $\kappa$ B signaling inhibitory effects, were reported. Tubulosine also exhibits various biological activities such as broad cytotoxicity in cancer cell lines, antimalarial activity, HIV reverse transcriptase-inhibitory activity and HIF-1 transcriptional inhibitory activity. (-)-Protoemetinol could be an excellent intermediate for the synthesis of various benzo[ $\alpha$ ]quinolizidine alkaloids including emetine and tubulosine because the structure of protoemetinol is identical to that of the core upper part of those alkaloids. The stereoselective synthesis of (-)-protoemetinol has been accomplished through nine steps from a known homoallylic amine. The key steps of the synthesis involve the efficient preparation of an aza-Claisen rearrangement (ACR) precursor using cross metathesis and amide enolate-induced ACR followed by acid-catalyzed transannulation for the elaboration of the benzo[ $\alpha$ ]quinolizidine skeleton and three stereogenic centers. This unique synthetic route envisages a unified and versatile strategy for the synthesis of 2,3-disubstituted benzo[ $\alpha$ ]quinolizidine.

### Biography

Changjin Lim has received his Bachelor's degree in Pharmacy from Seoul National University in 2011. He is currently a PhD candidate in the laboratory of Professor Young-Ger Suh at Seoul National University, South Korea.

[koryoi0709@gmail.com](mailto:koryoi0709@gmail.com)

### Notes: